|
Illumina Inc: Premium Company ProfilePublished by: Datamonitor Published: Apr. 22, 2008 - 46 Pages Table of Contents
AbstractIntroductionIllumina is one of the leading companies in genome and genotyping market. The company’s proprietary technology enables conversion of raw sequence data from the human genome into medically relevant information. The January 2007 acquisition of Solexa, a DNA sequencing company, has enabled Illumina to address a wide array of customer needs. Scope Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies Highlights The company offers products and services for the sequencing, genotyping and gene expression markets. Its customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations and biotechnology companies. The company’s total revenues increased manifold from $10 million in fiscal 2002 to $185 million in fiscal 2006, mainly due to the strong performance of the company’s consumable and instrumentation products in the market. The company is expected to see continued growth in its total revenues at a double-digit CAGR of 49% to reach $824 million between 2006 and 2010, which can be primarily attributable to the launch of number of new products, as well as the growth of its installed base of instruments. Reasons to Purchase Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization. Please note: This is delivered as a Zip file. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||